Nisa Leung 梁颕宇：Entrepreneurship and VC in China (LEAP BootCamp第四讲)

LEAP

LEAP诚邀启明创投Managing Partner 梁颕宇 (Nisa Leung) 解析中国医疗健康创业投资环境、机遇与市场策略

Li Ka Shing Center LK120

在将于7月20日周六举行的Entrepreneur BootCamp第四讲，LEAP邀请到启明创投Managing Partner梁颕宇（Nisa Leung），为大家介绍中国的创新环境、创业机遇和创投策略。中国市场和中国资本，是身在海外的创业者在项目启动前和创业过程中都应充分考虑的因素。巨大的市场和优惠的政策对于初创公司来说构成难以抗拒的吸引，而对在海外求学和工作多年的创业者来说，需要真正熟悉中国的市场环境和规则，方能有备而来，游刃有余。The China market and capital from China have become highly attractive and inevitable topics of discussion for new or established business nowadays. For entrepreneurs who are early in the process, it is greatly important to grasp a clear and current view of the enormous market and policy benefits of the China market. The more familiar we are with the business and policy environment in China, the better we will prepare ourselves for the challenges and opportunities to come, and therefore standing out among competitions. LEAP is excited to have Nisa Leung from Qiming Ventures for the the BootCamp series. Nisa will be discussing the opportunities and challenges faced by entrepreneurs who are interested in the China market during their preparation for or while entering the China market, especially in the field of biotech and life sciences. Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 4 billion in assets and investment in over 270 companies.Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan &amp; Lee Pharmaceutical, Zai Laboratories (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology, New Horizon Bio and Berry Oncology. She also oversees Qiming’s investments in Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics and Jacobio.梁颕宇（Nisa Leung）是医疗健康创投领域的先驱和领军人物，入选2019年福布斯全球最佳创投人，此前被AsianVenture Capital Journal评选为AVCJ2017年度创业投资人士。基于其丰富的投资经验和对中国市场、创业环境与行业策略的洞悉，Nisa将为大家带来一堂精彩的创业中国课：<ul><li>阐述创业者在中国应如何识别商业机遇，有效落实商业计划</li></ul><ul><li>解析中国创业创新环境，及如何规避商业、法律和监管风险</li></ul>

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

Nisa Leung 梁颕宇：Entrepreneurship and VC in China (LEAP BootCamp第四讲)

More events from LEAP

Discover more events from LEAP, from Science & Tech to other experiences you might love.

Nisa Leung 梁颕宇：Entrepreneurship and VC in China (LEAP BootCamp第四讲)

More events from LEAP

Discover more events from LEAP, from Science & Tech to other experiences you might love.

You might also like...

Browse more events with different dates, prices, and formats to find your next great experience.